FDA authorizes Novavax’s updated COVID-19 vaccine
Click Here to Manage Email Alerts
The FDA on Tuesday authorized Novavax’s updated COVID-19 vaccine for emergency use in adolescents and adults, giving the country a third vaccine option heading into the fall and winter respiratory diseases season.
People aged 12 years or older who have been previously vaccinated against COVID-19 and have not received one of the recently updated COVID-19 messenger RNA vaccines are now eligible to receive one dose of the Novavax vaccine, the FDA said. Previously unvaccinated patients should receive two doses.
Unlike the updated mRNA vaccines made by Moderna and Pfizer-BioNTech — which were already approved by the FDA — the Novavax vaccine is a protein-based shot that uses an adjuvant to spur the immune system.
All three updated vaccines were designed to protect against circulating SARS-CoV-2 variants and have been recommended by the CDC.
In August, Novavax said its updated vaccine induced neutralizing antibody responses to emerging variants.
The company expects doses of the vaccine to be available “in thousands of locations across the U.S. in the coming days, including CVS Pharmacy and Rite Aid.”
References:
- FDA authorized updated Novavax COVID-19 vaccine formulated to better protect against currently circulating variants. https://www.fda.gov/news-events/press-announcements/fda-authorizes-updated-novavax-covid-19-vaccine-formulated-better-protect-against-currently. Published Oct. 3, 2023. Accessed Oct. 3, 2023.
- Novavax 2023-2024 COVID-19 vaccine now authorized and recommended for use in the U.S. https://ir.novavax.com/press-releases/2023-10-03-Novavax-2023-2024-COVID-19-Vaccine-Now-Authorized-and-Recommended-for-Use-in-the-U-S. Published Oct. 3, 2023. Accessed Oct. 3, 2023.
Collapse
Press Release
Read more about
Click Here to Manage Email Alerts